报价延迟最少15分钟:2025/07/21 07:13 EDT
盘前时段
|
||||
|
3.06 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.18
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.26/-2.41
|
|
企业价值
9.62M
|
| 资产负债 |
|
每股账面净值
7.79
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
16.00M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 07:13 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase. |
